Angiopoietin-like proteins in multiple sclerosis

Rabeah Al-Temaimi 1, Preethi Cherian 2, Mohamed Abu-Farha 2, Raed Alroughani 3

Affiliations

15 May 2019

-

doi: 10.1016/j.jneuroim.2019.02.006

Abstract

Angiopoietin-like proteins (ANGPTLs) are a group of proteins with functions in lipid metabolism, angiogenesis, and inflammation. Here, we investigated their involvement in multiple sclerosis (MS) progression and response to treatment in 100 MS patients and 77 healthy controls. ANGPTLs significantly associated with MS progression and response to therapy. High ANGPTL6 levels associated with slow disease progression and good response to fingolimod treatment and low ANGPTL4 associated with poor response to natalizumab treatment. Therefore, we propose high ANGPTL4 and 6 levels as markers for positive response to MS treatments either natalizumab or fingolimod respectively. Further investigations into their role in MS is warranted.

Keywords: Angiopoietin-like proteins; Fingolimod; Multiple sclerosis; Natalizumab.

Similar articles

Plasma protein profiling reveals candidate biomarkers for multiple sclerosis treatment.

Bedri SK, Nilsson OB, Fink K, Månberg A, Hamsten C, Ayoglu B, Manouchehrinia A, Nilsson P, Olsson T, Hillert J, Grönlund H, Glaser A.PLoS One. 2019 May 29;14(5):e0217208. doi: 10.1371/journal.pone.0217208. eCollection 2019.PMID: 31141529 Free PMC article.

Serum neurofilaments increase at progressive multifocal leukoencephalopathy onset in natalizumab-treated multiple sclerosis patients.

Dalla Costa G, Martinelli V, Moiola L, Sangalli F, Colombo B, Finardi A, Cinque P, Kolb EM, Haghikia A, Gold R, Furlan R, Comi G.Ann Neurol. 2019 Apr;85(4):606-610. doi: 10.1002/ana.25437. Epub 2019 Mar 5.PMID: 30761586

Anti-JCV serology during natalizumab treatment: Review and meta-analysis of 17 independent patient cohorts analyzing anti-John Cunningham polyoma virus sero-conversion rates under natalizumab treatment and differences between technical and biological sero-converters.

Schwab N, Schneider-Hohendorf T, Hoyt T, Gross CC, Meuth SG, Klotz L, Foley JF, Wiendl H.Mult Scler. 2018 Apr;24(5):563-573. doi: 10.1177/1352458517728814. Epub 2017 Aug 29.PMID: 28847222 Review.

Soluble serum VCAM-1, whole blood mRNA expression and treatment response in natalizumab-treated multiple sclerosis.

Petersen ER, Søndergaard HB, Oturai AB, Jensen P, Sorensen PS, Sellebjerg F, Börnsen L.Mult Scler Relat Disord. 2016 Nov;10:66-72. doi: 10.1016/j.msard.2016.09.001. Epub 2016 Sep 6.PMID: 27919501

A review of the evidence for a natalizumab exit strategy for patients with multiple sclerosis.

Sellner J, Rommer PS.Autoimmun Rev. 2019 Mar;18(3):255-261. doi: 10.1016/j.autrev.2018.09.012. Epub 2019 Jan 11.PMID: 30639651 Review.

References

https://pubmed.ncbi.nlm.nih.gov/

Page Navigation